All episodes

What does the future hold for people living with diabetes? In this episode, our host Vivienne Parry together with diabetes advocates Bastian Hauck, Renza Scibilia and Christian Collin dives into recent advances in diabetes prevention, screening, and therapeutics - from GLP-1 drugs to innovative community-driven screening strategies. But as science accelerates, can our health systems and societies keep up? Join us for an eye-opening conversation on equity, access, and the power of community in reshaping diabetes care.

In this lively episode of Diabetes Insights, Prof. Francesco Rubino (King’s College London) and Dr. Louis Aronne (Weill Cornell Medicine) join Vivienne Parry to debate one of the biggest questions in obesity care: will next-generation medications make bariatric surgery obsolete?

Drawing on decades of clinical experience and new trial evidence, they explore whether powerful GLP-1-based therapies and combination drugs can rival the life-changing outcomes of surgery. From costs and complications to patient preferences and the hidden biology of obesity, they unpack how a new era of multi-modal treatment is reshaping care.

🎧 Tune in for sharp insights, respectful disagreement and...

In this episode, Dr. Melissa Thomas (Eli, Lilly & Company), Dr. Elizabeth Niemoller (Sanofi) and Prof. Michele Solimena (Helmholtz Zentrum München & Technical University of Dresden) join host Vivienne Parry to examine how partnerships between academia and industry are transforming diabetes research and care.

They discuss the culture shift from cautious collaboration to dynamic, mission-driven partnerships and how initiatives like INNODIA and the Innovative Medicines Initiative (IMI) are delivering real progress for patients. From translational breakthroughs to embedding patient advocates in clinical trial design, they explore why diverse perspectives, early regulatory foresight and shared goals are essential to accelerating therapeutic...

Today on Diabetes Insights, Prof. Raphael Scharfmann (INSERM, France) and Dr. Valeria Sordi (San Raffaele Diabetes Research Institute, Italy) join our host, Vivienne Parry to discuss the progress and remaining challenges in creating functional, insulin-producing beta cells from stem cells.

From the fundamental biology of pancreatic development to translational protocols for generating clinical-grade cells, our experts highlight how far the field has advanced and what hurdles remain before cell replacement therapies become a routine option for people with diabetes. They explore key questions around immune rejection, scalability, long-term viability of transplanted cells, and how the research community is navigating the...

In this episode, Professors Hood Thabit (University of Manchester, UK) and Helen Murphy (University of East Anglia, Norwich, UK) join Vivienne Parry and EASD to discuss the opportunities and persistent challenges in diabetes care in hospitals and pregnancy.

The conversation examines how diabetes technology - from continuous glucose monitoring (CGM) to hybrid closed-loop systems - is improving outcomes for people with diabetes in inpatient settings and for pregnant women with type 1 diabetes. The guests reflect on recent advances, national implementation success stories from the NHS, and gaps that still exist in gestational and type 2 diabetes care.

A compelling...

In this episode, we explore the fascinating history, fall, and resurgence of GIP (glucose-dependent insulinotropic polypeptide) in diabetes therapy. Once overshadowed by GLP-1, GIP is now back in the spotlight, thanks to dual and triple agonist therapies like tirzepatide. Experts discuss how GIP signaling in the brain may influence appetite and weight regulation, why early studies underestimated its therapeutic value, and what the future holds for multi-agonist drug development in metabolic disease.
Join Prof. Michael Nauck from the University of Bochum, Dr. Alice Adriaenssens from UCL and our host, Vivienne Perry as they revisit the incretin story, unpack recent breakthroughs...

In this episode, we explore the evolving world of cell therapy in type 1 diabetes. Professor James Shaw (Newcastle University), Dr Timothy Kieffer (University of British Columbia & Fractal Health), and Dr Trevor Reichman (University of Toronto) join EASD to discuss the established role of islet transplants and the exciting promise of stem cell–derived islets.

The conversation covers the clinical realities of pancreas and islet cell transplants, the challenges of immunosuppression, and how scalable, gene-edited stem cell therapies could shape the future of diabetes care.

From early trial successes to the potential of immune-evasive cells and gene therapies for GLP-1...

Today’s episode is special, as the topic was requested by members of the Early Career Academy. The spotlight is on work-life balance in academic medicine and research.

Dr Anna Krook from the Karolinska Institute in Sweden and Dr Benoit Gauthier from the Andalusian Molecular Biology and Regenerative Medicine Centre – CABIMER with the Ministry of Health of Andalusia in Spain, delve into the critical topic of work-life balance for everyone but specifically, early career academics.

Listen in as they discuss the unique challenges faced during this demanding period, including securing grants, managing teaching responsibilities, and navigating personal relationships. The conversation...

In this episode Diabetes Perspectives, Prof. Partha Kar, National Specialty Advisor for Diabetes with NHS England, shares how the UK became the first country in the world to offer universal access to continuous glucose monitors and hybrid closed-loop systems for people with type 1 diabetes.

Prof. Kar discusses the challenges of clinical inertia, the crucial role of patient advocacy, and how data-driven outcomes persuaded policymakers to invest in diabetes technology. He also offers lessons for healthcare leaders worldwide and explains why success isn’t just about funding but about listening to those living with the condition.

Join us for a practical,...

In this episode, Prof. Emma Ahlqvist (Lund University) and Prof. Matthias Blüher (University of Leipzig) join host Vivienne Parry to explore the future of type 2 diabetes. They unpack the shift from a one-size-fits-all approach to one that embraces stratified and personalised care.

From using machine learning to define diabetes subtypes to applying AI tools for screening, they share how new approaches could enable earlier diagnosis, better treatment choices, and improved outcomes. With obesity increasingly recognised as a chronic disease and not merely a lifestyle issue, they also discuss the need for broader access to therapies - and how stigma...